KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Assets Average (2016 - 2025)

Rigel Pharmaceuticals has reported Assets Average over the past 15 years, most recently at $378.1 million for Q4 2025.

  • For Q4 2025, Assets Average rose 149.22% year-over-year to $378.1 million; the TTM value through Dec 2025 reached $378.1 million, up 149.22%, while the annual FY2025 figure was $338.8 million, 140.96% up from the prior year.
  • Assets Average for Q4 2025 was $378.1 million at Rigel Pharmaceuticals, up from $224.6 million in the prior quarter.
  • Over five years, Assets Average peaked at $378.1 million in Q4 2025 and troughed at $116.2 million in Q3 2023.
  • A 5-year average of $163.4 million and a median of $145.1 million in 2022 define the central range for Assets Average.
  • Biggest five-year swings in Assets Average: tumbled 37.23% in 2022 and later surged 149.22% in 2025.
  • Year by year, Assets Average stood at $176.9 million in 2021, then dropped by 29.38% to $124.9 million in 2022, then dropped by 6.94% to $116.3 million in 2023, then skyrocketed by 30.46% to $151.7 million in 2024, then surged by 149.22% to $378.1 million in 2025.
  • Business Quant data shows Assets Average for RIGL at $378.1 million in Q4 2025, $224.6 million in Q3 2025, and $191.4 million in Q2 2025.